These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3953009)

  • 1. [DNAse II from phagocytes in the study of the pathogenesis of systemic lupus erythematosus].
    Matul'skaia LI; Klimov VIu; Riazantseva TA; Pleskovskaia GN
    Vopr Med Khim; 1986; 32(1):32-4. PubMed ID: 3953009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The uptake and degradation of DNA is impaired in macrophages and dendritic cells from NZB/W F(1) mice.
    Ogawa Y; Yoshinaga T; Yasuda K; Nishikawa M; Takakura Y
    Immunol Lett; 2005 Oct; 101(1):32-40. PubMed ID: 15979158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of systemically expanded activated T cell clones in MRL/lpr and NZB/W F1 lupus model mice.
    Zhou G; Fujio K; Sadakata A; Okamoto A; Yu R; Yamamoto K
    Clin Exp Immunol; 2004 Jun; 136(3):448-55. PubMed ID: 15147346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
    Enghard P; Langnickel D; Riemekasten G
    Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-nucleosome antibodies and T-cell response in systemic lupus erythematosus.
    Fournel S; Muller S
    Ann Med Interne (Paris); 2002 Dec; 153(8):513-9. PubMed ID: 12610425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental use of murine lupus models.
    Peng SL
    Methods Mol Med; 2004; 102():227-72. PubMed ID: 15286389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic lupus erythematosus: disease or syndrome?].
    Font J; Cardellach F
    Med Clin (Barc); 1985 Apr; 84(16):657-9. PubMed ID: 3875769
    [No Abstract]   [Full Text] [Related]  

  • 9. Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice.
    Alleva DG; Kaser SB; Beller DI
    J Immunol; 1997 Dec; 159(11):5610-9. PubMed ID: 9548504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice.
    Hsu TC; Huang CY; Chiang SY; Lai WX; Tsai CH; Tzang BS
    Eur J Pharmacol; 2008 Jan; 579(1-3):382-9. PubMed ID: 18031733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic administration of interleukin-4 expressing plasmid DNA delays the development of glomerulonephritis and prolongs survival in lupus-prone female NZB x NZW F1 mice.
    Hayashi T; Hasegawa K; Sasaki Y; Mori T; Adachi C; Maeda K
    Nephrol Dial Transplant; 2007 Nov; 22(11):3131-8. PubMed ID: 17670770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
    Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental approach to the pathogenesis of systemic lupus erythematosus].
    Lambert PH; Creighton D; Goodman R; Bankhurst A; Mischer PA
    J Urol Nephrol (Paris); 1972 Dec; 78(12):973-80. PubMed ID: 4350279
    [No Abstract]   [Full Text] [Related]  

  • 14. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Animal models in lupus].
    Meyer O
    Rev Rhum Mal Osteoartic; 1981 Dec; 48(12):817-25. PubMed ID: 6801750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner.
    Drake CG; Rozzo SJ; Hirschfeld HF; Smarnworawong NP; Palmer E; Kotzin BL
    J Immunol; 1995 Mar; 154(5):2441-7. PubMed ID: 7868910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine models of cutaneous involvement in lupus erythematosus.
    Ghoreishi M; Dutz JP
    Autoimmun Rev; 2009 May; 8(6):484-7. PubMed ID: 19239927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
    Borel P; Benkhoucha M; Weber MS; Zamvil SS; Santiago-Raber ML; Lalive PH
    Int Immunol; 2008 Oct; 20(10):1313-9. PubMed ID: 18687587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin and systemic lupus erythematosus.
    McMurray RW
    Ann Med Interne (Paris); 1996; 147(4):253-8. PubMed ID: 8952744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of lupus erythematosus with simultaneous reference to diagnostic characteristics].
    Sönnichsen V
    Dermatol Monatsschr; 1972 Jul; 158(7):474-84. PubMed ID: 4115170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.